149 related articles for article (PubMed ID: 16895176)
41. Endothelins and venous tone in DOCA-salt hypertension.
van den Meiracker AH
J Hypertens; 2002 Apr; 20(4):587-9. PubMed ID: 11910286
[No Abstract] [Full Text] [Related]
42. Bosentan and overcirculation-induced experimental pulmonary arterial hypertension.
Ullmann MV; Gorenflo M
Circulation; 2003 Dec; 108(23):e157; author reply e157. PubMed ID: 14662693
[No Abstract] [Full Text] [Related]
43. Bosentan in essential hypertension.
Haynes WG; Ferro CJ; Webb DJ
N Engl J Med; 1998 Jul; 339(5):346; author reply 347. PubMed ID: 9696644
[No Abstract] [Full Text] [Related]
44. Update on endothelins - biology and clinical implications.
Hunley TE; Kon V
Pediatr Nephrol; 2001 Sep; 16(9):752-62. PubMed ID: 11511995
[TBL] [Abstract][Full Text] [Related]
45. Endothelins in health and disease: an overview.
Goldie RG
Clin Exp Pharmacol Physiol; 1999 Feb; 26(2):145-8. PubMed ID: 10065336
[TBL] [Abstract][Full Text] [Related]
46. Endothelin-1: a mediator of pulmonary hypertension?
MacLean MR
Pulm Pharmacol Ther; 1998; 11(2-3):125-32. PubMed ID: 9918744
[No Abstract] [Full Text] [Related]
47. The role of endothelin in hypertension.
Rothermund L; Paul M
Curr Opin Nephrol Hypertens; 1998 Jul; 7(4):451-6. PubMed ID: 9690046
[TBL] [Abstract][Full Text] [Related]
48. Endothelin-1 and the pulmonary vascular response to altitude: a new therapeutic target?
Rubin LJ
Circulation; 2006 Sep; 114(13):1350-1. PubMed ID: 17000920
[No Abstract] [Full Text] [Related]
49. Porcine intrinsic pulmonary and systemic vascular tone is endothelin-dependent.
Weitzberg E; Rudehill A; Modin A; Lundberg JM
Acta Physiol Scand; 1994 Dec; 152(4):433-4. PubMed ID: 7701945
[No Abstract] [Full Text] [Related]
50. [Endothelin receptor antagonism in routine clinical care].
Riemekasten G
Krankenpfl J; 2005; 43(7-10):245. PubMed ID: 16515314
[No Abstract] [Full Text] [Related]
51. Endothelin-receptor antagonists in pulmonary hypertension.
Dupuis J
Lancet; 2001 Oct; 358(9288):1113-4. PubMed ID: 11597660
[No Abstract] [Full Text] [Related]
52. Endothelin-1: an interesting peptide or an important mediator in pulmonary diseases?
Hay DW
Pulm Pharmacol Ther; 1998; 11(2-3):141-6. PubMed ID: 9918746
[No Abstract] [Full Text] [Related]
53. Molecular and cellular biology of endothelin and its receptors--Part I.
Lüscher TF; Oemar BS; Boulanger CM; Hahn AW
J Hypertens; 1993 Jan; 11(1):7-11. PubMed ID: 8382241
[No Abstract] [Full Text] [Related]
54. Performance-enhancing effects of non-selective endothelin receptor antagonist.
Ostojic SM; Stojanovic M; Calleja-Gonzalez J; Olcina G; Sekulic D; Hoffman JR
Int J Cardiol; 2014 Feb; 171(2):294-7. PubMed ID: 24342407
[No Abstract] [Full Text] [Related]
55. [Endothelial receptor antagonists].
Bornkessel B
Med Monatsschr Pharm; 1997 Jul; 20(7):174-6. PubMed ID: 9333711
[No Abstract] [Full Text] [Related]
56. Aprocitentan and the endothelin system in resistant hypertension.
Clozel M
Can J Physiol Pharmacol; 2022 Jul; 100(7):573-583. PubMed ID: 35245103
[TBL] [Abstract][Full Text] [Related]
57. Blockade of the renin-angiotensin and endothelin systems on progressive renal injury.
Muenter K; Dashwood MR
Hypertension; 2001 May; 37(5):E13. PubMed ID: 11358955
[No Abstract] [Full Text] [Related]
58. [Antihypertensive treatment in patients with diabetes mellitus].
Zukowska-Szczechowska E; Gosek K; Grzeszczak W
Pol Arch Med Wewn; 2002 Oct; 108(4):1023-30. PubMed ID: 12642948
[No Abstract] [Full Text] [Related]
59. Molecular and cellular biology of endothelin and its receptors--Part II.
Lüscher TF; Oemar BS; Boulanger CM; Hahn AW
J Hypertens; 1993 Feb; 11(2):121-6. PubMed ID: 8385170
[No Abstract] [Full Text] [Related]
60. Tracleer. Tablets ease symptoms of rare lung disorder.
Nursing; 2002 Feb; 32(2):18. PubMed ID: 11924160
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
